Otto T, Suhr J, Rübben H
Westdeutsches Tumorzentrum Essen.
Urologe A. 2003 Nov;42(11):1461-5. doi: 10.1007/s00120-003-0458-5.
The great majority of phytotherapeutic, homeopathic and anthroposophical medicines are subject to the regulations in their respective field of application, implying a simple licensing process. In contrast with conventional medications in the area of oncology, some unconventional agents are given in observation studies without the prior testing of quality, side effects and efficacy that is normal in oncology. Unconventional therapeutics cannot be considered equivalent to placebo preparations. Since they may have an immunomodulatory action, one cannot exclude possible long-term adverse effects, including progression of tumors. To date there is no clear indication for routine use of unconventional therapeutic agents in urological oncology. A scientific evaluation according to the criteria of evidence-based medicine is required. This article presents proven results of treatment with unconventional medicines in urooncology against the background of the respective spectrum of methods.
绝大多数植物疗法药物、顺势疗法药物和人智学药物在其各自应用领域都受相关法规约束，这意味着许可程序简单。与肿瘤学领域的传统药物不同，一些非传统药物在观察性研究中使用时，没有进行肿瘤学中常规的质量、副作用和疗效预先测试。非传统疗法不能被视为等同于安慰剂制剂。由于它们可能具有免疫调节作用，不能排除可能的长期不良影响，包括肿瘤进展。迄今为止，在泌尿肿瘤学中尚无常规使用非传统治疗药物的明确指征。需要根据循证医学标准进行科学评估。本文在各自方法范围内介绍了泌尿肿瘤学中使用非传统药物治疗的已证实结果。
